Equally clinical and preclinical studies have implicated glutamatergic process dysfunction during the pathophysiology of mood Conditions. Particularly, fast reductions in depressive symptoms are already observed in reaction to subanesthetic doses in the glutamatergic modulator racemic (Notice that mTORC1 signaling also regulates inflammatory equipm